Bayer Moves Anti-Thrombotic Into Phase III For Two Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer is set to begin Phase III trials for its antithrombotic agent BAY 59-7939 for a general venous thromboembolism indication following promising Phase II results, the company announced June 12